TR200202109T2 - 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri - Google Patents

5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri

Info

Publication number
TR200202109T2
TR200202109T2 TR2002/02109T TR200202109T TR200202109T2 TR 200202109 T2 TR200202109 T2 TR 200202109T2 TR 2002/02109 T TR2002/02109 T TR 2002/02109T TR 200202109 T TR200202109 T TR 200202109T TR 200202109 T2 TR200202109 T2 TR 200202109T2
Authority
TR
Turkey
Prior art keywords
fluorobenzyl
oxy
naphthyl
methyl
crystals
Prior art date
Application number
TR2002/02109T
Other languages
English (en)
Inventor
Oe Takayuki
Ueno Hiroaki
Maruyama Akira
Masuda Katsuhiko
Original Assignee
Mitsubishi Chemical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corporation filed Critical Mitsubishi Chemical Corporation
Publication of TR200202109T2 publication Critical patent/TR200202109T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Cosmetics (AREA)

Abstract

Mevcut bulus, 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion' un kararli ve yeni C tipi kristallerine iliskin olup, bunlar asagidaki hastaliklarin tedavisine yönelik terapötik aktif bilesen olarak kullanilmaya uygundur: diyabet ve komplikasyonlari, hiperlipidemi ve komplikasyonlari, hiperürisemi, lösemi ve pankreatit.
TR2002/02109T 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri TR200202109T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20

Publications (1)

Publication Number Publication Date
TR200202109T2 true TR200202109T2 (tr) 2002-11-21

Family

ID=18233859

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2002/02103T TR200202103T2 (tr) 1998-11-20 1999-11-19 ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''
TR2002/02109T TR200202109T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri
TR2002/02110T TR200202110T2 (tr) 1998-11-20 1999-11-19 "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
TR2001/01901T TR200101901T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2002/02103T TR200202103T2 (tr) 1998-11-20 1999-11-19 ''5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri''

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR2002/02110T TR200202110T2 (tr) 1998-11-20 1999-11-19 "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
TR2001/01901T TR200101901T2 (tr) 1998-11-20 1999-11-19 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri

Country Status (23)

Country Link
US (3) US6541493B1 (tr)
EP (1) EP1131310B1 (tr)
JP (1) JP3784001B2 (tr)
KR (1) KR100652326B1 (tr)
CN (1) CN1326449A (tr)
AT (1) ATE315552T1 (tr)
AU (1) AU1185100A (tr)
BR (1) BR9916795A (tr)
CA (1) CA2351727C (tr)
CZ (1) CZ20011763A3 (tr)
DE (1) DE69929476T2 (tr)
ES (1) ES2257104T3 (tr)
HU (1) HUP0104139A3 (tr)
ID (1) ID30064A (tr)
IL (1) IL143177A0 (tr)
NO (1) NO20012444L (tr)
NZ (1) NZ512429A (tr)
PL (1) PL348502A1 (tr)
PT (1) PT1131310E (tr)
TR (4) TR200202103T2 (tr)
TW (2) TWI250156B (tr)
WO (1) WO2000031055A1 (tr)
ZA (1) ZA200104081B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID30064A (id) * 1998-11-20 2001-11-01 Mitsibishi Chemical Corp Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion
CN1423639A (zh) * 1999-11-19 2003-06-11 奥索-麦克尼尔药品公司 5－[[6－[(2－氟苯基)甲氧基]－2－萘基]甲基]－2,4－噻唑烷二酮的多种固态形式
US20030045553A1 (en) * 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
PL2303267T3 (pl) * 2008-02-04 2013-11-29 Pfizer Ltd Polimorficzna postać pochodnej [1,2,4]triazolo[4,3-a]pirydyny do leczenia chorób zapalnych

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
ID30064A (id) * 1998-11-20 2001-11-01 Mitsibishi Chemical Corp Kristal-kristal 5[(2-fluorobenzil) oksi-2-naftil) metil]-2, 4-tiazolidinedion

Also Published As

Publication number Publication date
IL143177A0 (en) 2002-04-21
JP2002530392A (ja) 2002-09-17
ZA200104081B (en) 2002-05-20
TR200202103T2 (tr) 2002-11-21
EP1131310A1 (en) 2001-09-12
PT1131310E (pt) 2006-05-31
TWI272944B (en) 2007-02-11
DE69929476D1 (de) 2006-04-06
AU1185100A (en) 2000-06-13
ES2257104T3 (es) 2006-07-16
NO20012444L (no) 2001-07-18
NZ512429A (en) 2003-11-28
JP3784001B2 (ja) 2006-06-07
KR100652326B1 (ko) 2006-11-29
CN1326449A (zh) 2001-12-12
PL348502A1 (en) 2002-05-20
TR200202110T2 (tr) 2002-10-21
BR9916795A (pt) 2002-04-09
US20030158241A1 (en) 2003-08-21
US6541493B1 (en) 2003-04-01
NO20012444D0 (no) 2001-05-18
KR20010101033A (ko) 2001-11-14
EP1131310B1 (en) 2006-01-11
DE69929476T2 (de) 2006-09-14
US20060149075A1 (en) 2006-07-06
TW200613291A (en) 2006-05-01
CA2351727A1 (en) 2000-06-02
ID30064A (id) 2001-11-01
CZ20011763A3 (cs) 2001-10-17
ATE315552T1 (de) 2006-02-15
TR200101901T2 (tr) 2002-04-22
TWI250156B (en) 2006-03-01
WO2000031055A1 (en) 2000-06-02
CA2351727C (en) 2008-09-23
HUP0104139A3 (en) 2003-12-29
HUP0104139A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
NO993281L (no) Tynn, komfortabel interlabial absorberende struktur
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
CY1107438T1 (el) Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις των
TR200101539T2 (tr) Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri.
ATE209049T1 (de) Absorbierender artikel
BR9106432A (pt) Indolona neuroprotetora e derivados correlatos
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE257703T1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
TR200103179A2 (tr) Integrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AP2000001881A0 (en) 2-(Purine-9-YL)-tetrahydrofuran-3,4 4-diol derivatives.
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
EP1449850A4 (en) WITH HUMAN CDR GRAVED ANTIBODIES AND ANTIBODY FRAGMENTS THEREOF
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
DE60014369D1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
EP0786995A4 (tr)
WO2003028715A3 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
DE60128100D1 (de) Analgetisches arzneimittel
TR200101901T2 (tr) 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-Tiyazolidin dion kristalleri
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.